Keywords: Almirall, Third-quarter 2010 financial results
Spain’s Almirall sees downturn in 3rd-qtr 2010 sales and incomes, but in line with guidance
Article | 16 November 2010
Spain's largest drugmaker Almirall (ALM: SM) said that third quarter 2010 net sales were slightly eroded (-3.5%) to 676.5 millillion euros ($926.8 million) ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- US Supreme Court says patent settlement can "sometimes" be illegal
- Actavis and Kissei file law suits against Sandoz and Hetero over Rapaflo patent
